INSMED INC Business Combination, Contingent Consideration, Liability, Noncurrent
INSMED INC (INSM) had Business Combination, Contingent Consideration, Liability, Noncurrent of $170.55 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Noncurrent $170.55M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Noncurrent $270.31M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $314.34M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Noncurrent $259.60M.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $170.55M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $270.31M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $314.34M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $259.60M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $180.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $159.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $144.20M 10-K · filed 2026-02-19 |
| 2024-09-30 | $157.60M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $101.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $63.70M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $84.60M 10-K · filed 2025-02-20 |
| 2023-09-30 | $69.90M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $46.40M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $38.60M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $51.10M 10-K · filed 2024-02-22 |
| 2022-09-30 | $51.80M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $55.60M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $66.12M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $75.67M 10-K · filed 2023-02-23 |
| 2021-09-30 | $76.49M 10-Q · filed 2021-10-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |